WACKER BIOSOLUTIONS
In 2020, WACKER BIOSOLUTIONS lifted its sales 1.3 percent to €246.1 million (2019: €243.0 million), chiefly due to volume growth in biologics and cyclodextrins. Reduced volumes for a number of products had a dampening effect on sales growth. In regional terms, sales were very positive in Europe, but declined in the Americas and Asia.
At €38.1 million, EBITDA was significantly higher year over year (2019: €31.1 million). The increase was due to volume growth and an improved cost structure. The EBITDA margin was 15.5 percent (2019: 12.8 percent).
Capital expenditures climbed year over year to €19.9 million (2019: €13.2 million). That was a rise of 50.8 percent. One investment focus was the new biologics production plant in Amsterdam.
As of December 31, 2020, the division had 764 employees (Dec. 31, 2019: 754).
| Download XLS |
|
|
|
|
|
||||||
€ million |
|
2020 |
|
2019 |
|
2018 |
|
2017 |
|
2016 |
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Total sales |
|
246.1 |
|
243.0 |
|
227.0 |
|
205.9 |
|
206.4 |
EBITDA |
|
38.1 |
|
31.1 |
|
23.5 |
|
37.5 |
|
37.0 |
EBITDA margin (%) |
|
15.5 |
|
12.8 |
|
10.4 |
|
18.2 |
|
17.9 |
EBIT |
|
21.6 |
|
14.0 |
|
9.8 |
|
26.1 |
|
25.7 |
Capital expenditures |
|
19.9 |
|
13.2 |
|
17.9 |
|
15.7 |
|
9.1 |
R&D expenses |
|
5.7 |
|
6.4 |
|
6.3 |
|
6.0 |
|
6.2 |
Employees (December 31, number) |
|
764 |
|
754 |
|
709 |
|
533 |
|
510 |